BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data

Reuters12-18 23:31
BUZZ-Obesity pill maker Structure gains after Lilly's pill shows promising trial data

** Structure Therapeutics shares GPCR.O up about 3% at $61.80

** Eli Lilly LLY.N trial data shows its oral pill, orforglipron, helped patients maintain weight loss after switching from injectable GLP-1 drugs

** J.P. Morgan says Lilly's data "is a good read-across" for GPCR's oral pill, aleniglipron, whose trial data is due H2 2026

** GPCR shares had doubled on Dec 8 after aleni trial data showed weight loss of up to 11.3% after 36 weeks of treatment

** Stock now up about 126% YTD, after a 33.5% drop in 2024

** JPM thinks both orfo and aleni could be effective options for patients who want to move away from injectables long term

(Reporting by Siddhi Mahatole)

((siddhi.mahatole@thomsonreuters.com))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment